A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects.
Michael J FosslerVirginia SchmithStephen A GreeneLauren LohmerMichael S KramerKelly ArscottIan E JamesMark A DemitrackPublished in: CNS drugs (2021)
The findings from the first-in-human study support further evaluation of TRV250, a G-protein selective DOR agonist, in the treatment of acute migraine.